| 1.37 0.02 (1.48%) | 06-24 13:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.3 | 1-year : | 2.81 |
| Resists | First : | 1.97 | Second : | 2.41 |
| Pivot price | 1.55  |
|||
| Supports | First : | 1.25 | Second : | 1.04 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.73 |
| MA(100) : | 2.34 |
MA(250) : | 6.44 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 5.5 |
| RSI | RSI(14): 29.1 |
|||
| 52-week | High : | 17.63 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENVB ] has closed above bottom band by 28.2%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.43 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.34 - 1.35 | 1.35 - 1.36 |
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Sun, 21 Jun 2026
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Thu, 18 Jun 2026
ENVERIC BIOSCIENCES INC (ENVB) Stock Chart - ChartMill
Thu, 18 Jun 2026
ENVB News | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Tue, 16 Jun 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention - Business Wire
Tue, 09 Jun 2026
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Business Wire
Tue, 09 Jun 2026
Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 10.8 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 887 (K) |
| EPS | -22.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.8 % |
| Return on Equity (ttm) | -183.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|